摘要
AD的鉴别诊断任因与其它痴呆的重叠特征而存在困难。用于AD鉴别诊断的生物标记物可以提高该病的诊断价值并确保恰当治疗。该研究目的在于评价两个作为AD鉴别诊断血清生物标记物的新抗原表位Tau片断的潜力。 新抗原表位Tau片断在一群代表性的患有AD,MCI,其它痴呆或非痴呆向关的记忆力减退的受试者中进行评价。两种新抗原表位Tau片断是ADAM10产生的片断(Tau-A)和半胱天冬酶3产生的片断(Tau-C)。该研究已分别用两种竞争性ELISA检测Tau-A和Tau-C测量这些片断的血清水平。 Tau-A和Tau-C能将患有AD和MCI的受试者与其它痴呆患者区分(p < 0.0042 和p < 0.05),且Tau-A能将AD和MCI患者与非痴呆相关的记忆力减退受试者区分(p <0.05)。Tau-A与CSF生物标记物t-Tau和p-Tau相比,显示了明显更高的对AD和MCI受试者与其它痴呆患者的区分。Tau-A 区分AD和MCI受试者与其它痴呆患者的能力被与CSF Aβ1-42, t-Tau/Aβ1-42 和 p-Tau/Aβ1-42比较。当CSF生物标记物与年龄和BMI与Tau-A联合使用时(AUC = 0.87,95% CI: 0.75-0.94)(p < 0.0001),诊断组间的区分度显著提高。结论是,该研究表明血清中检测出的新抗原表位Tau片断能为AD鉴别诊断提供指导。
关键词: 老年痴呆,鉴别诊断,血清生物标记物,Tau片断。
Current Alzheimer Research
Title:Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease
Volume: 12 Issue: 9
Author(s): D. Inekci, K. Henriksen, T. Linemann, M.A. Karsdal, A. Habib, C. Bisgaard, F.B. Eriksen and O.J. Vilholm
Affiliation:
关键词: 老年痴呆,鉴别诊断,血清生物标记物,Tau片断。
摘要: Differential diagnosis of AD is still a challenge due to overlapping features with other types of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value of the disease and ensure an appropriate treatment of patients. The aim of this study was to evaluate the potential of two neo-epitope fragments of Tau as serum biomarkers for differential diagnosis of AD.
The neo-epitope fragments of Tau were assessed in a cross-sectional cohort of subjects with AD, MCI, other dementias or subjects with non-dementia related memory complaints. The two Tau neo-epitope fragments were an ADAM10-generated fragment (Tau-A) and a caspase-3-generated fragment (Tau-C). The serum levels of the fragments were measured by two competitive ELISAs detecting Tau-A and Tau-C, respectively.
Tau-A and Tau-C were able to separate subjects with AD and MCI from those with other dementias (p < 0.0042 and p < 0.05), and Tau-A could also discriminate between AD and MCI patients and subjects with non-dementia related memory complaints (p < 0.05). Tau-A showed a significantly greater discrimination between AD and MCI subjects and patients with other dementias when compared to CSF biomarkers t-Tau and p-Tau. The ability of Tau-A to differentiate between AD and MCI from other dementias was comparable with CSF Aβ1-42, t-Tau/Aβ1-42 and p-Tau/Aβ1-42. The separation between the diagnostic groups was significantly improved when the CSF biomarkers as well as age and BMI were used in combination with Tau-A (AUC = 0.87, 95% CI: 0.75-0.94) (p < 0.0001). In conclusion, this study shows that a neoepitope fragment of Tau detected in serum can provide guidance on the differential diagnosis of AD.
Export Options
About this article
Cite this article as:
D. Inekci, K. Henriksen, T. Linemann, M.A. Karsdal, A. Habib, C. Bisgaard, F.B. Eriksen and O.J. Vilholm , Serum Fragments of Tau for the Differential Diagnosis of Alzheimer's Disease, Current Alzheimer Research 2015; 12 (9) . https://dx.doi.org/10.2174/1567205012666150710111211
DOI https://dx.doi.org/10.2174/1567205012666150710111211 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Viral Induced Oxidative and Inflammatory Response in Alzheimer’s Disease Pathogenesis with Identification of Potential Drug Candidates: A Systematic Review using Systems Biology Approach
Current Neuropharmacology Heat Shock Proteins: Therapeutic Drug Targets for Chronic Neurodegeneration?
Current Pharmaceutical Biotechnology UCP2 and CFH Gene Variants with Genetic Susceptibility to Schizophrenia in Turkish Population
Endocrine, Metabolic & Immune Disorders - Drug Targets Placebos Used in Clinical Trials for Chinese Herbal Medicine
Recent Patents on Inflammation & Allergy Drug Discovery Calpain Inhibition: A Therapeutic Strategy Targeting Multiple Disease States
Current Pharmaceutical Design New Pharmacologic Approaches to Prevent Thromboembolism in Patients with Atrial Fibrillation
Current Vascular Pharmacology Integrated System Pharmacology and <i>In Silico</i> Analysis Elucidating Neuropharmacological Actions of <i>Withania somnifera</i> in the Treatment of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Roles of TRAF6 in Central Nervous System
Current Neuropharmacology Biochemistry and Neurobiology of Prosaposin: A Potential Therapeutic Neuro-Effector
Central Nervous System Agents in Medicinal Chemistry Docking-based 3D-QSAR Studies of Phosphodiesterase 9A Inhibitors
Letters in Drug Design & Discovery Type 3 Diabetes Mellitus: A Novel Implication of Alzheimers Disease
Current Topics in Medicinal Chemistry Consequences of Iron Accumulation in Microglia and its Implications in Neuropathological Conditions
CNS & Neurological Disorders - Drug Targets Structural Exploration of Synthetic Chromones as Selective MAO-B Inhibitors: A Mini Review
Combinatorial Chemistry & High Throughput Screening Intestinal Absorption and Presystemic Elimination of Various Chemical Constituents Present in GBE50 Extract, a Standardized Extract of Ginkgo biloba Leaves
Current Drug Metabolism Review of Synthesis, Biological Assay and QSAR Studies of β-Secretase Inhibitors
Current Computer-Aided Drug Design Editorial: Early Recognition of Dementia in Primary Care- Current Issues and Concepts
Current Alzheimer Research Hutchinson-Gilford Progeria Syndrome (Hgps) and Application of Gene Therapy Based Crispr/Cas Technology as A Promising Innovative Treatment Approach
Recent Patents on Biotechnology Development of Bivalent Acetylcholinesterase Inhibitors as Potential Therapeutic Drugs for Alzheimers Disease
Current Pharmaceutical Design Disentangling the Role of the Tau Gene Locus in Sporadic Tauopathies
Current Alzheimer Research Alzheimers Disease and Retinal Neurodegeneration
Current Alzheimer Research